Effect of treatment with 5 ‐lipoxygenase inhibitor VIA‐2291 (atreleuton) on coronary plaque progression: a serial CT angiography study

Conclusions VIA‐2291 resulted in slowed plaque progression compared with placebo across different plaque subtypes in patients with recent ACS (http://ClinicalTrials.gov NCT00358826).

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fclc.22646

Source: Clinical Cardiology - November 23, 2016 Category: Cardiology Authors: Suguru Matsumoto, Reda Ibrahim, Jean C. Gr égoire, Philippe L. L'Allier, Josephine Pressacco, Jean‐Claude Tardif, Matthew J. Budoff Tags: Clinical Investigations Source Type: research